MT-UAVIONIX
24.3.2021 23:10:12 CET | Business Wire | Press release
uAvionix Corporation today announced it achieved DoD AIMS Mk XIIB certification of its first Identification Friend or Foe (IFF) transponder, the RT-2087/ZPX-B . With this certification, ZPX-B becomes the world’s smallest, certified micro-IFF transponder, reducing Size, Weight, and Power Consumption (SWaP) characteristics of typical IFF transponders by more than 90%, and at less than half the size, one-third the weight, and one fourth the power consumption of other Unmanned Aircraft Systems (UAS) targeted IFF solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005976/en/
The certification, issued by the Department of Defense (DoD) Air Traffic Control Radar Beacon System Identification Friend or Foe Program Office (AIMS PO), attests to its IFF capability and its interoperability with military equipment fielded by NATO and its allied countries. Incorporation of IFF technology into small, tactical, and attritable platforms allows them full participation into the cross-troop, cross-service branch, and cross-nation collaboration and situational awareness that prevents fratricide.
The ZPX-B enables IFF capability for small and tactical Group 1-4 UAS, thanks to its record-breaking SWaP at 3.3 in3 , 60 grams, and power consumption of only 3.5 Watts. Transmitting at 54dBm, ZPX-B provides civil transponder modes A, C, S, and ADS-B Out, as well as military modes 1, 2, 3, and 5 Levels 1 and 2 – all individually configurable. ADS-B In functionality provides situational awareness and Detect and Avoid (DAA) capabilities to the host platform. Crypto compatibility complies with AIMS 04-900A Option B, which includes the KIV-77 and KIV-79.
Passive IFF Reception for Situational Awareness
In addition to the ZPX-B, uAvionix introduces the ZPX-R, a passive ADS-B and Mode 5 Level 2 receiver for ground-based, shipborne, or airborne reception for situational awareness and DAA capability. Mode 5 Level 2 encrypted squitters enable situational awareness in areas where Mode 5 interrogators are absent, increasing the scalability of deployment. ZPX-R can provide data in multiple formats, including Open Mission Systems (OMS) for incorporation into tactical displays or ACAS Xu or similar DAA processors.
Unclassified Integration, Testing, and Demonstration with Crypto Emulation
For military programs or OEMs looking to integrate a micro-IFF into their platforms, ZPX-B incorporates an internal crypto-emulator that enables development and test independent of COMSEC-controlled equipment subject to onerous handling requirements.
For more information on the uAvionix line of defense products, including IFF transponders, receivers, GPS, and crypto emulators, visit https://uavionix.com/defense/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005976/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom